SI
Imperial
General Calculators
Addiction Medicine
Anesthesiology
Airway & Respiratory
BMI
Cardiac Surgery
Clinical Status Assessment
Intraoperative Monitoring
Obstetrics
Preoperative Assessment
ACC/AHA CV Risk Calculator (2013)Estimate 10-year risk for atherosclerotic cardiovascular diseaseRevised Cardiac Risk Index (Lee Criteria)Rapid pre-op assessment using the Revised Cardiac Risk IndexAsymptomatic ICA (Internal Carotid Artery) Stenosis Surgical Risk StratificationGupta Perioperative Cardiac RiskDetermine peri-operative risk for a wide array of surgeries.Postoperative Respiratory Failure Risk CalculatorEstimate risk of postoperative respiratory failureVSGNE Ruptured Abdominal Aortic Aneurysm (RAAA) Risk ScoreEstimate mortality after open repair of ruptured AAAPre-test probability of CAD (CAD consortium)Determine pre-test probability of coronary artery disease in patients with chest pain.Vascular Quality Initiative (VQI) Cardiac Risk Index (CRI) | Carotid EndarterectomyEstimate risk of post-op myocardial infarction after carotid endarterectomyVascular Quality Initiative (VQI) Cardiac Risk Index (CRI) | EVAREstimate risk of post-op myocardial infarction after EVARVascular Quality Initiative (VQI) Cardiac Risk Index (CRI) | Infra-inguinal BypassEstimate risk of post-op myocardial infarction after infra-inguinal bypassVascular Quality Initiative (VQI) Cardiac Risk Index (CRI) | Open AAA RepairEstimate risk of post-op myocardial infarction after open AAA repairVQI: Respiratory Adverse Event Risk Post Vascular SurgeryEstimate the risk of pneumonia or respiratory failure after vascular surgeryVascular Quality Initiative (VQI) 30-Day Stroke Risk Index for CEAEstimate risk of stroke within 30 days after carotid endarterectomyVascular Quality Initiative (VQI) 1-Year Mortality Risk Index for CEAEstimate probability of death within 1 year after carotid endarterectomyVascular Quality Initiative (VQI) Cardiac Risk Index (CRI) | Suprainguinal BypassEstimate risk of post-op myocardial infarction after suprainguinal bypassGeriatric-Sensitive Perioperative Cardiac Risk Index | GSCRIEstimate risk of perioperative myocardial infarction or cardiac arrest in patients over 65ASA Physical StatusClassification system for assessing the fitness of patients before surgery
Cardiac Surgery
Cardiology
Aortic Disease
Aortic Stenosis/Outflow
Arrhythmia
Atrial Fibrillation
Bleeding Risk
Coronary Artery Disease
ECG
Echocardiography
Heart Failure
Hypertension
Invasive Hemodynamics
Miscellaneous
Mitral Regurgitation
Mitral Stenosis
PCI and Cardiac Surgery
Pre-operative Assessment
Risk Scores
Shunts
Syncope
Treadmill Testing
Critical Care
Cardiac ICU
Cardiac Output - FickCalculate cardiac output, cardiac index, stroke volume and stroke volume indexKillip ClassEstimate mortality in myocardial infarctionTIMI Risk Score (NSTEMI)Guide therapeutic decisions in non-ST elevation MI. Shunt Fraction (Invasive)TIMI Risk Score (STEMI)Systemic Vascular ResistanceGRACEThe GRACE ACS risk calculator estimates risk of death following acute coronary syndrome (ACS)Mean Arterial Pressure (MAP) Calculate MAP
REFERENCE BOOK
KDIGO Clinical Practice Guideline for Acute Kidney Injury
AKI Definition Prevention and Treatment of AKI Contrast-induced AKI Dialysis Interventions for Treatment of AKI
Introduction and Methodology
Introduction
IntroductionGlomerular filtration rate and serum creatinineOliguria and anuriaAcute tubular necrosis (ATN)ARFRIFLE criteriaAKI: acute kidney injury/impairmentValidation studies using RIFLELimitations to current definitions for AKIRationale for a guideline on AKISummary
Methodology
IntroductionGroup member selection and meeting processEvidence selection, appraisal, and presentationOutcome selection judgments, values, and preferencesGrading the quality of evidence and the strength of recommendationsSPONSORSHIPDISCLAIMERSUPPLEMENTARY MATERIAL
AKI Definition
Definition and classification of AKI
IntroductionDefinition of AKIStaging AKI: Recommendations and RationaleResearch RecommendationsSupplementary materialRisk assessmentIntroductionRecommendations and RationaleResearch RecommendationsSupplementary material
Evaluation and general management of patients with and at risk for AKI
IntroductionRecommendations and RationaleResearch recommendationsSupplementary material
Clinical applications
IntroductionExamples of application of AKI definitionsEstimating baseline SCrExamples of application of AKI stagesUrine output vs. SCrTimeframe for diagnosis and stagingClinical judgmentPseudo-AKIAtypical AKISupplementary material
Diagnostic approach to alterations in kidney function and structure
Definitions of AKI, CKD and AKDGFR and SCrGFR/SCr algorithmOliguria as a measure of kidney functionKidney damageSmall kidneys as a marker of kidney damageIntegrated approach to AKI, AKD, and CKDSponsorshipDisclaimerSupplementary material
Prevention and Treatment of AKI
Hemodynamic monitoring and support for prevention and management of AKI
IntroductionFluids: Recommendations and RationaleAlbumin vs. SalineHydroxyethylstarch vs. SalineVasopressors: Recommendations and RationaleProtocolized Hemodynamic Management: Recommendations and RationaleProtocolized hemodynamic management strategies in septic shockGoal-directed therapy for hemodynamic support during the perioperative period in high-risk surgical patientsResearch RecommendationsSupplementary material
General supportive management of patients with AKI, including management of complications
Overview
Glycemic control and nutritional support
Glycemic control in critical illness: Recommendations and RationaleNutritional aspects in the prevention and treatment of critically ill patients with AKITotal Energy Intake: Recommendations and RationaleProtein Intake: Recommendations and RationaleNutrition route: Recommendations and RationalePediatrics ConsiderationsResearch RecommendationsSupplementary material
The use of diuretics in AKI
IntroductionRecommendations and RationaleMannitolResearch Recommendations
Vasodilator therapy: dopamine, fenoldopam, and natriuretic peptides
Dopamine for the prevention or treatment of AKI: Recommendations and RationaleFenoldopam for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsNatriuretic peptides for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsSupplementary Material
Growth factor intervention
Recombinant Human (rh) IGF-1: Recommendations and RationaleErythropoietinResearch RecommendationsSupplementary Material
Adenosine receptor antagonists
IntroductionRecommendations and RationaleResearch Recommendations
Prevention of aminoglycoside- and amphotericin-related AKI
Aminoglycoside nephrotoxicityTreatment of Infections: Recommendations and RationalePatients with Normal Kidney Function in Steady State: Recommendations and RationaleWhen Treatment with Multiple Daily Dosing is Used for More than 24 Hours: Recommendations and RationaleWhen Treatment with Single-Daily Dosing is Used for More than 48 Hours: Recommendations and RationaleTopical or Local Applications of Aminoglycosides: Recommendations and RationaleResearch RecommendationsAmphotericin B nephrotoxicity: Recommendations and RationaleTreatment of Systemic Mycoses or Parasitic Infections: Recommendations and RationaleResearch Recommendations
Other methods of prevention of AKI in the critically ill
On-pump vs. off-pump coronary artery bypass surgery: Recommendations and RationaleResearch RecommendationsN-ACETYLCYSTEINE (NAC): Recommendations and RationaleNAC in critically ill patients: Recommendations and RationaleSponsorshipDisclaimerSupplementary Material
Contrast-induced AKI
Contrast-induced AKI: definition, epidemiology, and prognosis
BackgroundRecommendations and RationaleEpidemiology of CI-AKIPrognosis of CI-AKIResearch RecommendationsSupplementary Material
Assessment of the population at risk for CI-AKI
Recommendations and RationaleRisk-factor questionnaireUrinary protein screeningOther risk factors of CI-AKIRisk models of CI-AKIPatients at Increased Risk for CI-AKI: Recommendations and RationaleNephrotoxicity of Gd chelatesNephrogenic systemic fibrosis (NSF)Supplementary Material
Nonpharmacological prevention strategies of CI-AKI
IntroductionDose/Volume of Contrast-Media Administration: Recommendations and RationaleRoute of administration of contrast mediaResearch RecommendationsSelection of a Contrast Agent: Recommendations and RationaleHigh-osmolar vs. iso-osmolar or low-osmolar contrast mediaLow-osmolar vs. iso-osmolar contrast mediai.a. Iodixanol vs. ioxaglatei.v. AdministrationResearch RecommendationsSupplementary Material
Pharmacological prevention strategies of CI-AKI
Fluid Administration: Recommendations and RationaleUse of oral fluids alone in patients at increased risk of CI-AKI: Recommendations and RationaleRole of nac in the prevention of CI-AKI: Recommendations and RationaleTheophylline: Recommendations and RationaleFenoldopam: Recommendations and RationaleStatins in the prevention of CI-AKISupplementary Material
Effects of hemodialysis or hemofiltration
Recommendations and RationaleSponsorshipDisclaimerSupplementary material
Dialysis Interventions for Treatment of AKI
Timing of renal replacement therapy in AKI
IntroductionRecommendations and RationalePediatric considerations
Research Recommendations
Supplementary material
Criteria for stopping renal replacement therapy in AKI
IntroductionWhen to discontinue RRT: Recommendations and RationaleUse of diuretics: Recommendations and RationalePediatric considerationsResearch Recommendations
Anticoagulation
IntroductionHow to decide to use anticoagulation: Recommendations and RationalePatients without an increased bleeding risk or impaired coagulation and not already receiving effective systemic anticoagulation: Recommendations and RationalePatients with increased bleeding risk who are not receiving anticoagulation: Recommendations and RationaleIn patients with heparin-induced thrombocytopenia: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Vascular access for renal replacement therapy in AKI
IntroductionUncuffed nontunneled dialysis catheter vs a tunneled catheter: Recommendations and RationaleWhen choosing a vein for insertion of a dialysis catheter in patients with AKI: Recommendations and RationaleUsing ultrasound guidance for dialysis catheter insertion: Recommendations and RationaleObtaining a chest radiograph promptly after placement and before first use of an internal jugular or subclavian dialysis catheter: Recommendations and RationaleTopical antibiotics: Recommendations and RationaleAntibiotic locks: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Dialyzer membranes for renal replacement therapy in AKI
IntroductionRecommendations and RationaleResearch Recommendations
Modality of renal replacement therapy for patients with AKI
IntroductionComplementary therapies in AKI patients: Recommendations and RationaleHemodynamically unstable patients: Recommendations and RationaleAKI patients with acute brain injury or other causes of increased intracranial pressure or generalized brain edema: Recommendations and RationaleProtocols for decreasing hemodynamic instability with intermittent RRTPeritoneal dialysisPediatric considerationsResearch RecommendationsSupplementary material
Buffer solutions for renal replacement therapy in patients with AKI
IntroductionBuffer solution: Recommendations and RationaleDialysis fluids and replacement fluids in patients with AKI: Recommendations and RationaleResearch RecommendationsSupplementary material
Dose of renal replacement therapy in AKI
IntroductionDosing: Recommendations and RationaleKt/V and Effluent Volume Rates: Recommendations and RationaleAdditional considerationsResearch RecommendationsSponsorshipDislcaimerSupplementary material
Organization and Acknowledgements
NoticeWork Group MembershipKDIGO Board MembersReference KeysAbbreviations and AcronymsAbstractForewordBiographic and Disclosure InformationAcknowledgmentsReferences
General Medicine
ICU AKI
APACHE IIEstimate mortality in the critically illContrast Nephropathy Post-PCIEstimate risk of AKI after percutaneous coronary interventionDialysis Risk After Cardiac Surgery (Cleveland Clinic Score by Thakar)Estimate risk of dialysis after cardiac surgery.Dialysis Risk After Cardiac Surgery (Mehta)Estimate the risk of dialysis after cardiac surgery (Mehta model)Fractional Excretion of SodiumDifferentiate pre-renal AKI from ATN.Fractional Excretion of UreaIdentify a pre-renal state in patients using diureticsSequential Organ Failure Assessment (SOFA)Document clinical severity in the ICU and predict mortalityPediatric Renal Angina IndexPredict acute kidney injury in critically ill childrenSTARRT-AKI Enrollment CriteriaDetermine if patients meet criteria for the STARRT-AKI study.Kinetic eGFR (KeGFR)Estimate GFR when creatinine is changing acutely (either rising or falling)PIM2Paediatric Index of Mortality, revised versionSerious Renal Dysfunction Post-PCIAssess risk of dialysis or severe increase in creatinine after PCICRRT Dosing CalculatorCalculate desired dose of dialysate in CRRTKDIGO AKI StagingClassification in acute kidney injury (AKI)
REFERENCE BOOK
KDIGO Clinical Practice Guideline for Acute Kidney Injury
AKI Definition Prevention and Treatment of AKI Contrast-induced AKI Dialysis Interventions for Treatment of AKI
Introduction and Methodology
Introduction
IntroductionGlomerular filtration rate and serum creatinineOliguria and anuriaAcute tubular necrosis (ATN)ARFRIFLE criteriaAKI: acute kidney injury/impairmentValidation studies using RIFLELimitations to current definitions for AKIRationale for a guideline on AKISummary
Methodology
IntroductionGroup member selection and meeting processEvidence selection, appraisal, and presentationOutcome selection judgments, values, and preferencesGrading the quality of evidence and the strength of recommendationsSPONSORSHIPDISCLAIMERSUPPLEMENTARY MATERIAL
AKI Definition
Definition and classification of AKI
IntroductionDefinition of AKIStaging AKI: Recommendations and RationaleResearch RecommendationsSupplementary materialRisk assessmentIntroductionRecommendations and RationaleResearch RecommendationsSupplementary material
Evaluation and general management of patients with and at risk for AKI
IntroductionRecommendations and RationaleResearch recommendationsSupplementary material
Clinical applications
IntroductionExamples of application of AKI definitionsEstimating baseline SCrExamples of application of AKI stagesUrine output vs. SCrTimeframe for diagnosis and stagingClinical judgmentPseudo-AKIAtypical AKISupplementary material
Diagnostic approach to alterations in kidney function and structure
Definitions of AKI, CKD and AKDGFR and SCrGFR/SCr algorithmOliguria as a measure of kidney functionKidney damageSmall kidneys as a marker of kidney damageIntegrated approach to AKI, AKD, and CKDSponsorshipDisclaimerSupplementary material
Prevention and Treatment of AKI
Hemodynamic monitoring and support for prevention and management of AKI
IntroductionFluids: Recommendations and RationaleAlbumin vs. SalineHydroxyethylstarch vs. SalineVasopressors: Recommendations and RationaleProtocolized Hemodynamic Management: Recommendations and RationaleProtocolized hemodynamic management strategies in septic shockGoal-directed therapy for hemodynamic support during the perioperative period in high-risk surgical patientsResearch RecommendationsSupplementary material
General supportive management of patients with AKI, including management of complications
Overview
Glycemic control and nutritional support
Glycemic control in critical illness: Recommendations and RationaleNutritional aspects in the prevention and treatment of critically ill patients with AKITotal Energy Intake: Recommendations and RationaleProtein Intake: Recommendations and RationaleNutrition route: Recommendations and RationalePediatrics ConsiderationsResearch RecommendationsSupplementary material
The use of diuretics in AKI
IntroductionRecommendations and RationaleMannitolResearch Recommendations
Vasodilator therapy: dopamine, fenoldopam, and natriuretic peptides
Dopamine for the prevention or treatment of AKI: Recommendations and RationaleFenoldopam for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsNatriuretic peptides for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsSupplementary Material
Growth factor intervention
Recombinant Human (rh) IGF-1: Recommendations and RationaleErythropoietinResearch RecommendationsSupplementary Material
Adenosine receptor antagonists
IntroductionRecommendations and RationaleResearch Recommendations
Prevention of aminoglycoside- and amphotericin-related AKI
Aminoglycoside nephrotoxicityTreatment of Infections: Recommendations and RationalePatients with Normal Kidney Function in Steady State: Recommendations and RationaleWhen Treatment with Multiple Daily Dosing is Used for More than 24 Hours: Recommendations and RationaleWhen Treatment with Single-Daily Dosing is Used for More than 48 Hours: Recommendations and RationaleTopical or Local Applications of Aminoglycosides: Recommendations and RationaleResearch RecommendationsAmphotericin B nephrotoxicity: Recommendations and RationaleTreatment of Systemic Mycoses or Parasitic Infections: Recommendations and RationaleResearch Recommendations
Other methods of prevention of AKI in the critically ill
On-pump vs. off-pump coronary artery bypass surgery: Recommendations and RationaleResearch RecommendationsN-ACETYLCYSTEINE (NAC): Recommendations and RationaleNAC in critically ill patients: Recommendations and RationaleSponsorshipDisclaimerSupplementary Material
Contrast-induced AKI
Contrast-induced AKI: definition, epidemiology, and prognosis
BackgroundRecommendations and RationaleEpidemiology of CI-AKIPrognosis of CI-AKIResearch RecommendationsSupplementary Material
Assessment of the population at risk for CI-AKI
Recommendations and RationaleRisk-factor questionnaireUrinary protein screeningOther risk factors of CI-AKIRisk models of CI-AKIPatients at Increased Risk for CI-AKI: Recommendations and RationaleNephrotoxicity of Gd chelatesNephrogenic systemic fibrosis (NSF)Supplementary Material
Nonpharmacological prevention strategies of CI-AKI
IntroductionDose/Volume of Contrast-Media Administration: Recommendations and RationaleRoute of administration of contrast mediaResearch RecommendationsSelection of a Contrast Agent: Recommendations and RationaleHigh-osmolar vs. iso-osmolar or low-osmolar contrast mediaLow-osmolar vs. iso-osmolar contrast mediai.a. Iodixanol vs. ioxaglatei.v. AdministrationResearch RecommendationsSupplementary Material
Pharmacological prevention strategies of CI-AKI
Fluid Administration: Recommendations and RationaleUse of oral fluids alone in patients at increased risk of CI-AKI: Recommendations and RationaleRole of nac in the prevention of CI-AKI: Recommendations and RationaleTheophylline: Recommendations and RationaleFenoldopam: Recommendations and RationaleStatins in the prevention of CI-AKISupplementary Material
Effects of hemodialysis or hemofiltration
Recommendations and RationaleSponsorshipDisclaimerSupplementary material
Dialysis Interventions for Treatment of AKI
Timing of renal replacement therapy in AKI
IntroductionRecommendations and RationalePediatric considerations
Research Recommendations
Supplementary material
Criteria for stopping renal replacement therapy in AKI
IntroductionWhen to discontinue RRT: Recommendations and RationaleUse of diuretics: Recommendations and RationalePediatric considerationsResearch Recommendations
Anticoagulation
IntroductionHow to decide to use anticoagulation: Recommendations and RationalePatients without an increased bleeding risk or impaired coagulation and not already receiving effective systemic anticoagulation: Recommendations and RationalePatients with increased bleeding risk who are not receiving anticoagulation: Recommendations and RationaleIn patients with heparin-induced thrombocytopenia: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Vascular access for renal replacement therapy in AKI
IntroductionUncuffed nontunneled dialysis catheter vs a tunneled catheter: Recommendations and RationaleWhen choosing a vein for insertion of a dialysis catheter in patients with AKI: Recommendations and RationaleUsing ultrasound guidance for dialysis catheter insertion: Recommendations and RationaleObtaining a chest radiograph promptly after placement and before first use of an internal jugular or subclavian dialysis catheter: Recommendations and RationaleTopical antibiotics: Recommendations and RationaleAntibiotic locks: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Dialyzer membranes for renal replacement therapy in AKI
IntroductionRecommendations and RationaleResearch Recommendations
Modality of renal replacement therapy for patients with AKI
IntroductionComplementary therapies in AKI patients: Recommendations and RationaleHemodynamically unstable patients: Recommendations and RationaleAKI patients with acute brain injury or other causes of increased intracranial pressure or generalized brain edema: Recommendations and RationaleProtocols for decreasing hemodynamic instability with intermittent RRTPeritoneal dialysisPediatric considerationsResearch RecommendationsSupplementary material
Buffer solutions for renal replacement therapy in patients with AKI
IntroductionBuffer solution: Recommendations and RationaleDialysis fluids and replacement fluids in patients with AKI: Recommendations and RationaleResearch RecommendationsSupplementary material
Dose of renal replacement therapy in AKI
IntroductionDosing: Recommendations and RationaleKt/V and Effluent Volume Rates: Recommendations and RationaleAdditional considerationsResearch RecommendationsSponsorshipDislcaimerSupplementary material
Organization and Acknowledgements
NoticeWork Group MembershipKDIGO Board MembersReference KeysAbbreviations and AcronymsAbstractForewordBiographic and Disclosure InformationAcknowledgmentsReferences
Illness Severity
Medical ICU
Neurologic ICU
Respiratory ICU
Sepsis
Trauma
Emergency
Airway
Burns
Chest Pain & Cardiac
General Medicine
ECG: Heart RateA-a GradientUsed to determine cause of hypoxemiaAnion GapCalculate anion gap for use in acid-base disorders.CHADS2 Score for AFAssess risk of stroke in atrial fibrillationCHA2DS2-VASc Score for AFReplacement for CHADS2 for stroke prediction in atrial fibrillationChild Pugh ScoreDetermine severity of cirrhosis.ECG: Corrected QTECG: Cycle LengthFractional Excretion of SodiumDifferentiate pre-renal AKI from ATN.MDRD eGFRCalculate eGFR using the MDRD formulaPrognosis after TIPSS using MELD ScoreOsmolal GapDetect unmeasured osmoles, such as toxic alcoholsPeak Expiratory Flow PredictionPneumonia risk (CURB-65)Estimate prognosis and determine disposition in community-acquired pneumoniaRanson's CriteriaEstimate mortality in patients with pancreatitis. Water Deficit in HypernatremiaDetermine water replacement in hypernatremiaCanadian Syncope Risk Score (CSRS)Estimate prognosis among patients presenting to emergency with syncopeROSIER scaleDetermine which patients are likely to have true stroke vs stroke mimicsModified Early Warning Score (MEWS)Identify patients who are at risk of clinical deterioration and who may require a higher level of care.Mean Arterial Pressure (MAP) Calculate MAPCentor Score (modified) for GAS PharyngitisEstimate likelihood of GAS pharyngitisMaintenance Fluid CalculationsDetermine maintenance IV fluid ratesOttawa chronic obstructive pulmonary disease risk scale (OCRS)Guide admission vs discharge in COPD exacerbationLight's CriteriaDetermine whether a pleural effusion is exudative or transudativeMcMahon Rhabdomyolysis Risk ScorePredict the risk of severe acute kidney injury or mortality in patients with rhabdomyolysisKocher Criteria for Septic ArthritisDetermine risk of septic arthritis in a child with an inflamed hipShock IndexA more sensitive quotient for circulatory shock than vital signs alone
Injuries & Trauma
Pediatrics ER
Psychiatry
Sepsis
Surgery
Thrombosis
Endocrinology
Diabetes
Electrolytes
Lipids
Obesity
Osteoporosis
Thyroid cancer
Gastroenterology
Diarrhea
GI Bleed
Hepatology
Autoimmune Hepatitis DiagnosisClarify the diagnose of autoimmune hepatitisChild Pugh ScoreDetermine severity of cirrhosis.Discriminant Function (Alcoholic Hepatitis)Emory Model (TIPSS)Prognosis after TIPSS using MELD ScorePrognosis in Alcoholic HepatitisEstimates prognosis in alcoholic hepatitis using the MELD scorePELD Score - Age Younger Than 12 yearsPELD (Pediatric End-Stage Liver Disease) is used for liver allocation in the OPTN match systemAlcoholism - Risk of RelapseAlcohol Relapse Risk after Liver TransplantSerum Ascites to Albumin Gradient (SAAG)Determine if ascites due to portal hypertension.FIB-4 for Noninvasive Diagnosis of Hepatic FibrosisNon-invasively identify hepatic fibrosisAPRI (AST to Platelet Ratio Index)Assess likelihood of fibrosis or cirrhosis non-invasively using AST and platelet count.NAFLD Fibrosis ScoreReduce the need for liver biopsy by identifying patients with non-alcoholic fatty liver disease likely or unlikely to have advanced fibrosisMELD Score - Age above 12 yearsScoring system used to rank prioritize candidates for liver transplantation, including MELD-Na used in the OPTN match systemAlcohol Relapse Risk after Liver TransplantMELD Score - Age above 12 yearsScoring system used to rank prioritize candidates for liver transplantation, including MELD-Na used in the OPTN match systemPELD Score - Age Younger Than 12 yearsPELD (Pediatric End-Stage Liver Disease) is used for liver allocation in the OPTN match systemUKELD ScoreThe United Kingdom Model for End-Stage Liver Disease (UKELD) predicts prognosis in chronic liver disease and can be used to prioritize for liver transplantationLille Model for Alcoholic HepatitisEstimate mortality in patients with severe alcoholic hepatitis not responding to corticosteroid therapy BE3A ScoreWhen to treat HCV in decompensated cirrhosis
Inflammatory Bowel Disease
Pancreatitis
Geriatrics
Predicting 3 Year Survival for Incident Elderly ESRD PatientsDetermine appropriateness for transplant referral in elderly patients starting dialysis
Cardiac & Cerebrovascular
Depression
Frailty
General Medicine
Geriatric Psychiatry
Kidney Disease
Neurocognitive Disorder
Hematology
Benign Hematology
Body Surface Area
Malignant Hematology
CMML Prognostic Scoring Systems (from Spain and Dusseldorf)Assess risk of progression to AML and early mortality in CMMLDiffuse Large B-Cell Lymphoma Prognosis (R-IPI)Determine prognosis in diffuse large B-cell lymphomaFollicular Lymphoma prognosisDetermine prognosis in follicular lymphoma (FLIPI)Acute GVHD GradingDetermine severity in acute graft versus host disease.Hodgkin's Disease | PrognosisEstimate prognosis in Hodgkin's disease.Hematopoietic cell transplantation - specific comorbidity index (HCT-CI)MDS Revised - International Prognostic Scoring System (IPSS-R)Assess mortality and progression to acute myeloid leukemia in myelodysplastic syndromeHodgkin's Marrow InvolvementEstimate likelihood of bone marrow involvement in Hodgkin's lymphoma.MDS Intnl Prognostic Scoring Sys (IPSS)Multiple Myeloma Prognosis (ISS)MASCC Febrile Neutropenia RiskAssess risk in febrile neutropenia and appropriateness for outpatient managementMDS Anemia - EPO/GCSF ResponseIdentify those with MDS likely to respond to stem-cell factors.MDS WHO Classification-based Prognostic Scoring System (WPSS)Estimate survival and risk of transformation to AML in myelodysplastic syndrome.MGUS PrognosisDetermine risk of malignant progression to myleoma or lymphoproliferative disorder.MIPI - Mantle Cell Lymphoma PrognosisEstimate prognosis in mantle cell lymphoma.DIPSS Prognosis in MyelofibrosisEstimate prognosis in myelofibrosis.Smoldering Multiple Myeloma PrognosisDetermine risk of progression to symptomatic multiple myeloma.Diffuse Large B-cell Lymphoma Prognosis (IPI24)Determine prognosis in diffuse large B-cell lymphoma.Diffuse Large B-cell Lymphoma Prognosis (NCCN-IPI)Estimate prognosis in diffuse large B-cell lymphomaDIPSS Plus Score for Prognosis in MyelofibrosisEstimate prognosis in myelofibrosis.Multiple Myeloma Prognosis (R-ISS)Revised international staging system for myelomaCLL-IPIThe International Prognostic Index for patients with chronic lymphocytic leukemiaExpected spleen size Provides upper limit of normal for spleen length and volume by ultrasound relative to body height and gender. MDS Revised - International Prognostic Scoring System (IPSS-R) Non-Age AdjustedAssess mortality and progression to acute myeloid leukemia in myelodysplastic syndrome using the non-age adjusted model
Sponsored
CNS International Prognostic Index in Diffuse Large B-Cell Lymphoma (CNS-IPI)Estimate risk of CNS relapse/progression in diffuse large B-cell lymphomaMALT Lymphoma prognosis (MALT-IPI)Estimate prognosis in MALT lymphomaKhorana risk scoreEstimate risk of chemotherapy-associated thrombosisCLL BALL Score for Relapsed/Refractory CLLSokal Score for CMLEstimate survival in CMLEUTOS Score for Chronic Myelogenous Leukemia (CML)Predict outcomes after CML treatment, adjusted for tyrosine kinase treatments CMML CPSS-MolEstimate risk of progression to AML in those with CMML using molecular genetics dataInternational Prognostic Scoring System for Waldenstrom MacroglobulinemiaEstimate prognosis with the IPPSWM
Infectious Disease
MELD Score - Age above 12 yearsScoring system used to rank prioritize candidates for liver transplantation, including MELD-Na used in the OPTN match system
Antibiotic Dosing
Clostridium Difficile
Diagnostic Criteria
Febrile Neutropenia
Fever in Infants
Liver
Respiratory Tract Infection
Sepsis
Tuberculosis
Medical Administration
Medical Imaging
Mental Health
Addictions
Anxiety
Bipolar
Cognition
Depression
Hamilton Depression Rating Scale (HAM-D or HDRS)Determine severity of depressionModified SAD PERSONS ScaleAssess depression with the modified SAD PERSONS ScalePatient Health Questionnaire-9 (PHQ-9)Screening tool to assist in identifying major depressive disorderGeriatric Depression ScaleA questionnaire to screen for depression in geriatric populationsPatient Health Questionnaire-2 (PHQ-2)Ultra-brief screening for depressive disordersAltman Self-Rating Mania Scale (ASRM)5 question scale to screen and stage severity of hypomania/maniaYoung Mania Rating Scale (YMRS)11 question scale to grade the severity of maniaPatient Health Questionnaire-4 (PHQ-4)Ultra-Brief Screening for Anxiety and DepressionCAGE Questionnaire4 question screening for alcohol problemsEdinburgh Postnatal Depression Scale (EPDS)10 question screener for postpartum depressionBipolar Spectrum Diagnostic Scale (BSDS)20 question screener for bipolar spectrum diagnosisWho Five Well Being Index (WHO-5)​5 questions to measure mental well-beingInformant Questionnaire on Cognitive Decline in the Elderly (IQCODE)16 question geriatric cognitive screenerMajor Depression Inventory (MDI)12 question depression severity scalePost Traumatic Stress Disorder (PCL-C)17 question self-report for Post Traumatic Stress DisorderBrief Psychiatric Rating Scale (BPRS)18 clinical questions to assess severity of consolidated symptoms Generalized Anxiety Disorder 2 (GAD-2)Ultra-brief screening for anxiety disorders
REFERENCE BOOK
Screening for Depression | CTFPHC
Eating Disorder
Obsessive Compulsive Disorder
Pediatrics
Post Traumatic Stress
Psychosis
Psychosomatic
Treatment Side Effects
Nephrology
Acute Kidney Injury
APACHE IIEstimate mortality in the critically illContrast Nephropathy Post-PCIEstimate risk of AKI after percutaneous coronary interventionDialysis Risk After Cardiac Surgery (Cleveland Clinic Score by Thakar)Estimate risk of dialysis after cardiac surgery.Dialysis Risk After Cardiac Surgery (Mehta)Estimate the risk of dialysis after cardiac surgery (Mehta model)Fractional Excretion of SodiumDifferentiate pre-renal AKI from ATN.Fractional Excretion of UreaIdentify a pre-renal state in patients using diureticsSequential Organ Failure Assessment (SOFA)Document clinical severity in the ICU and predict mortalityPediatric Renal Angina IndexPredict acute kidney injury in critically ill childrenSTARRT-AKI Enrollment CriteriaDetermine if patients meet criteria for the STARRT-AKI study.Kinetic eGFR (KeGFR)Estimate GFR when creatinine is changing acutely (either rising or falling)PIM2Paediatric Index of Mortality, revised versionSerious Renal Dysfunction Post-PCIAssess risk of dialysis or severe increase in creatinine after PCICRRT Dosing CalculatorCalculate desired dose of dialysate in CRRTNCDR AKI and Dialysis Risk after PCIEstimate risk of AKI and dialysis after PCIAdvanced CKD after AKI Risk IndexEstimate risk of advanced chronic kidney disease after acute kidney injuryMayo AKI Risk after Primary Total Hip ArthroplastyEstimate perioperative risk of acute kidney injuryNSAID risk of AKI or hyperkalemiaCalculator to predict risk of AKI or hyperkalemia within 30 days after initiation of prescription NSAIDs in adults 66 years and older.McMahon Rhabdomyolysis Risk ScorePredict the risk of severe acute kidney injury or mortality in patients with rhabdomyolysisKDIGO AKI StagingClassification in acute kidney injury (AKI)
REFERENCE BOOK
KDIGO Clinical Practice Guideline for Acute Kidney Injury
AKI Definition Prevention and Treatment of AKI Contrast-induced AKI Dialysis Interventions for Treatment of AKI
Introduction and Methodology
Introduction
IntroductionGlomerular filtration rate and serum creatinineOliguria and anuriaAcute tubular necrosis (ATN)ARFRIFLE criteriaAKI: acute kidney injury/impairmentValidation studies using RIFLELimitations to current definitions for AKIRationale for a guideline on AKISummary
Methodology
IntroductionGroup member selection and meeting processEvidence selection, appraisal, and presentationOutcome selection judgments, values, and preferencesGrading the quality of evidence and the strength of recommendationsSPONSORSHIPDISCLAIMERSUPPLEMENTARY MATERIAL
AKI Definition
Definition and classification of AKI
IntroductionDefinition of AKIStaging AKI: Recommendations and RationaleResearch RecommendationsSupplementary materialRisk assessmentIntroductionRecommendations and RationaleResearch RecommendationsSupplementary material
Evaluation and general management of patients with and at risk for AKI
IntroductionRecommendations and RationaleResearch recommendationsSupplementary material
Clinical applications
IntroductionExamples of application of AKI definitionsEstimating baseline SCrExamples of application of AKI stagesUrine output vs. SCrTimeframe for diagnosis and stagingClinical judgmentPseudo-AKIAtypical AKISupplementary material
Diagnostic approach to alterations in kidney function and structure
Definitions of AKI, CKD and AKDGFR and SCrGFR/SCr algorithmOliguria as a measure of kidney functionKidney damageSmall kidneys as a marker of kidney damageIntegrated approach to AKI, AKD, and CKDSponsorshipDisclaimerSupplementary material
Prevention and Treatment of AKI
Hemodynamic monitoring and support for prevention and management of AKI
IntroductionFluids: Recommendations and RationaleAlbumin vs. SalineHydroxyethylstarch vs. SalineVasopressors: Recommendations and RationaleProtocolized Hemodynamic Management: Recommendations and RationaleProtocolized hemodynamic management strategies in septic shockGoal-directed therapy for hemodynamic support during the perioperative period in high-risk surgical patientsResearch RecommendationsSupplementary material
General supportive management of patients with AKI, including management of complications
Overview
Glycemic control and nutritional support
Glycemic control in critical illness: Recommendations and RationaleNutritional aspects in the prevention and treatment of critically ill patients with AKITotal Energy Intake: Recommendations and RationaleProtein Intake: Recommendations and RationaleNutrition route: Recommendations and RationalePediatrics ConsiderationsResearch RecommendationsSupplementary material
The use of diuretics in AKI
IntroductionRecommendations and RationaleMannitolResearch Recommendations
Vasodilator therapy: dopamine, fenoldopam, and natriuretic peptides
Dopamine for the prevention or treatment of AKI: Recommendations and RationaleFenoldopam for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsNatriuretic peptides for the prevention or treatment of AKI: Recommendations and RationaleResearch RecommendationsSupplementary Material
Growth factor intervention
Recombinant Human (rh) IGF-1: Recommendations and RationaleErythropoietinResearch RecommendationsSupplementary Material
Adenosine receptor antagonists
IntroductionRecommendations and RationaleResearch Recommendations
Prevention of aminoglycoside- and amphotericin-related AKI
Aminoglycoside nephrotoxicityTreatment of Infections: Recommendations and RationalePatients with Normal Kidney Function in Steady State: Recommendations and RationaleWhen Treatment with Multiple Daily Dosing is Used for More than 24 Hours: Recommendations and RationaleWhen Treatment with Single-Daily Dosing is Used for More than 48 Hours: Recommendations and RationaleTopical or Local Applications of Aminoglycosides: Recommendations and RationaleResearch RecommendationsAmphotericin B nephrotoxicity: Recommendations and RationaleTreatment of Systemic Mycoses or Parasitic Infections: Recommendations and RationaleResearch Recommendations
Other methods of prevention of AKI in the critically ill
On-pump vs. off-pump coronary artery bypass surgery: Recommendations and RationaleResearch RecommendationsN-ACETYLCYSTEINE (NAC): Recommendations and RationaleNAC in critically ill patients: Recommendations and RationaleSponsorshipDisclaimerSupplementary Material
Contrast-induced AKI
Contrast-induced AKI: definition, epidemiology, and prognosis
BackgroundRecommendations and RationaleEpidemiology of CI-AKIPrognosis of CI-AKIResearch RecommendationsSupplementary Material
Assessment of the population at risk for CI-AKI
Recommendations and RationaleRisk-factor questionnaireUrinary protein screeningOther risk factors of CI-AKIRisk models of CI-AKIPatients at Increased Risk for CI-AKI: Recommendations and RationaleNephrotoxicity of Gd chelatesNephrogenic systemic fibrosis (NSF)Supplementary Material
Nonpharmacological prevention strategies of CI-AKI
IntroductionDose/Volume of Contrast-Media Administration: Recommendations and RationaleRoute of administration of contrast mediaResearch RecommendationsSelection of a Contrast Agent: Recommendations and RationaleHigh-osmolar vs. iso-osmolar or low-osmolar contrast mediaLow-osmolar vs. iso-osmolar contrast mediai.a. Iodixanol vs. ioxaglatei.v. AdministrationResearch RecommendationsSupplementary Material
Pharmacological prevention strategies of CI-AKI
Fluid Administration: Recommendations and RationaleUse of oral fluids alone in patients at increased risk of CI-AKI: Recommendations and RationaleRole of nac in the prevention of CI-AKI: Recommendations and RationaleTheophylline: Recommendations and RationaleFenoldopam: Recommendations and RationaleStatins in the prevention of CI-AKISupplementary Material
Effects of hemodialysis or hemofiltration
Recommendations and RationaleSponsorshipDisclaimerSupplementary material
Dialysis Interventions for Treatment of AKI
Timing of renal replacement therapy in AKI
IntroductionRecommendations and RationalePediatric considerations
Research Recommendations
Supplementary material
Criteria for stopping renal replacement therapy in AKI
IntroductionWhen to discontinue RRT: Recommendations and RationaleUse of diuretics: Recommendations and RationalePediatric considerationsResearch Recommendations
Anticoagulation
IntroductionHow to decide to use anticoagulation: Recommendations and RationalePatients without an increased bleeding risk or impaired coagulation and not already receiving effective systemic anticoagulation: Recommendations and RationalePatients with increased bleeding risk who are not receiving anticoagulation: Recommendations and RationaleIn patients with heparin-induced thrombocytopenia: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Vascular access for renal replacement therapy in AKI
IntroductionUncuffed nontunneled dialysis catheter vs a tunneled catheter: Recommendations and RationaleWhen choosing a vein for insertion of a dialysis catheter in patients with AKI: Recommendations and RationaleUsing ultrasound guidance for dialysis catheter insertion: Recommendations and RationaleObtaining a chest radiograph promptly after placement and before first use of an internal jugular or subclavian dialysis catheter: Recommendations and RationaleTopical antibiotics: Recommendations and RationaleAntibiotic locks: Recommendations and RationalePediatric considerationsResearch RecommendationsSupplementary material
Dialyzer membranes for renal replacement therapy in AKI
IntroductionRecommendations and RationaleResearch Recommendations
Modality of renal replacement therapy for patients with AKI
IntroductionComplementary therapies in AKI patients: Recommendations and RationaleHemodynamically unstable patients: Recommendations and RationaleAKI patients with acute brain injury or other causes of increased intracranial pressure or generalized brain edema: Recommendations and RationaleProtocols for decreasing hemodynamic instability with intermittent RRTPeritoneal dialysisPediatric considerationsResearch RecommendationsSupplementary material
Buffer solutions for renal replacement therapy in patients with AKI
IntroductionBuffer solution: Recommendations and RationaleDialysis fluids and replacement fluids in patients with AKI: Recommendations and RationaleResearch RecommendationsSupplementary material
Dose of renal replacement therapy in AKI
IntroductionDosing: Recommendations and RationaleKt/V and Effluent Volume Rates: Recommendations and RationaleAdditional considerationsResearch RecommendationsSponsorshipDislcaimerSupplementary material
Organization and Acknowledgements
NoticeWork Group MembershipKDIGO Board MembersReference KeysAbbreviations and AcronymsAbstractForewordBiographic and Disclosure InformationAcknowledgmentsReferences
Chronic Kidney Disease
Fluids & Electrolytes
Glomerulonephritis
Hemodialysis
Hypertension
Nephrolithiasis
PD
PD Candidacy (MATCH-D)Assess candidacy for peritoneal dialysis3-Month Mortality in Incident Elderly ESRD PatientsEstimate the risk of early death (at 3 months) in elderly patients starting dialysis.Predicting 3 Year Survival for Incident Elderly ESRD PatientsDetermine appropriateness for transplant referral in elderly patients starting dialysisPredicting 3 Year Survival for Incident Elderly ESRD PatientsDetermine appropriateness for transplant referral in elderly patients starting dialysis
REFERENCE BOOK
Access Care and Complications Management
Sponsored
OverviewDisclaimer & Use of the Guide
Catheter Insertion and Care
Preoperative Management
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes Evaluation
Perioperative and Intraoperative Management
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes Evaluation
Postoperative Management
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes Evaluation
Chronic Care of Peritoneal Dialysis Catheter
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Noninfectious Complications
Pericatheter and Subcutaneous Leaks
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationManagementReferences
Peritoneal Catheter Obstruction
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Hernia
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Abdominal Discomfort During Infusion and Drain
Key AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Pneumoperitoneum (Shoulder Pain)
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Hemoperitoneum
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Hydrothorax
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Catheter Adapter Disconnect or Fracture of Peritoneal Catheter
Key AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Infectious Complications: Peritonitis Management
Initial Empiric Management of Peritonitis
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationInitial Empiric Management of PeritonitisStaphyloccocus aureus PeritonitisEnterococcus PeritonitisStreptococcus PeritonitisPseudomonas aeruginosa PeritonitisGram-negative Bacilli Organism PeritonitisPolymicrobial PeritonitisCulture-negative PeritonitisFungal PeritonitisMycobacterium PeritonitisPeritonitis TerminologyCoagulase-negative StaphylococciRelapsing and Repeat PeritonitisReferencesDisclaimer
Infectious Complications: Management of the Exit-site/Tunnel Infection
Introduction
IntroductionKey AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationDiagnosis and Management of Exit-site/Tunnel InfectionReferencesDisclaimer
Antibiotic Dosing Guidelines
Oral Antibiotics Used in Exit-site and Tunnel InfectionsExit-site Antibiotic ProphylaxisIntraperitoneal Antibiotic Dosing Recommendations for CAPD PatientsIntermittent Dosing of Antibiotics in Automated Peritoneal Dialysis (APD)References
Surgical Salvage Procedures for Infectious Complications
Simultaneous Catheter Replacement for Relapsing Peritonitis
Key AssessmentsKey ActivitiesPatient EducationOutcomes Evaluation
Exit-Site and Tunnel Infections
Key AssessmentsKey ActivitiesPatient EducationOutcomes EvaluationReferences
Appendix
Preoperative and Postoperative PD Catheter Insertion Instructions for PatientsPeritoneal ImagingPrinciples of Accurate Peritoneal Dialysis Effluent Sampling and CulturingPeritoneal Effluent Culture Laboratory ProcessingPeritonitis Rate CalculationsDifferential Diagnosis of Non-infectious Cloudy EffluentProviding for a Safe Environment for Peritoneal DialysisNormal Bacterial Flora of the Human Body
Preoperative Mapping
IntroductionPreoperative Mapping Using a Catheter SampleStencil-Based Preoperative MappingPreoperative Mapping for Upper Abdominal and Presternal CathetersProcedure Day MappingReferencesCalculating Peritonitis Rates: An ExampleAuthor AffiliationsAccess Care and Complications Management   link ⇲
REFERENCE BOOK
CSN PD Adequacy Guidelines and Recommendations 2011
Maintenance of RRF
Measurement of RRFUse of Antihypertensive Agents and Diuretis to Preserve RRF
Small-Solute Clearance
Prescription and Targets
Volume Management
Maintenance of Euvolemia and Diagnosis of HypervolemiaTreatment of HypervolemiaAssessment and Management of BP
Management of CV Disease in PD Patients
Dyslipidemia
Nutrition in PD
NutritionNutritional SupplementsCorrection of Impared Anabolism, Acidosis, and Gastroparesis
Management of Hyperglycemia
Glycemic ControlGlucose-Sparing Strategies
Introduction
OverviewMethods and Process for Guideline DevelopmentFigure 1Figure 2Figure 3
Maintenance of RRF
Measurement of RRF
Overview
Use of Antihypertensive Agents and Diuretics to Preserve RRF
OverviewBackground
Research
Overview
Small-Solute Clearance
Prescriptions and Targets
OverviewBackground
Volume Management
Maintenance of Euvolemia and Diagnosis of Hypervolemia
OverviewBackground
Treatment of Hypervolemia
OverviewBackground
Assessment and Management of BP
OverviewBackground
Management of CV Disease in PD Patients
Dyslipidemia
OverviewBackground
Coronary Artery Disease/Chronic Heart Failure
Overview
Research
Overview
Nutrition in PD
Nutrition
OverviewBackground
Nutritional Supplements
OverviewBackground
Correction of Impaired Anabolism, Acidosis, and Gastroparesis
OverviewBackground
Research
Overview
Management of Hyperglycemia
Glycemic Control
OverviewBackground
Glucose-Sparing Strategies
OverviewBackgroundDisclosuresReferences
REFERENCE BOOK
PD Prescription Quick Reference Guide
Sponsored
REFERENCE BOOK
PD Prescription Management Guide
Sponsored
Pathology
Polycystic Kidney Disease
Thrombotic Microangiopathy
Transplant
eGFR
Neurology / Neurosurgery
Arteriovenous Malformation
Coma/Level of Consciousness
Dementia/Neurodegenerative
Dermatome Map
Functional Outcome
Head & Neck Trauma
Headache
Intracerebral Hemorrhage
Ischemic Stroke
Movement Disorder
Multiple Sclerosis & Demyelinating Disease
Neurophysiology
Seizure
Subarachnoid Hemorrhage
Thrombotic Microangiopathy
Obstetrics
Oncology
Body Surface Area
Breast Cancer
Head & Neck Cancer Staging
Malignant Hematology
CMML Prognostic Scoring Systems (from Spain and Dusseldorf)Assess risk of progression to AML and early mortality in CMMLDiffuse Large B-Cell Lymphoma Prognosis (R-IPI)Determine prognosis in diffuse large B-cell lymphomaFollicular Lymphoma prognosisDetermine prognosis in follicular lymphoma (FLIPI)Acute GVHD GradingDetermine severity in acute graft versus host disease.Hodgkin's Disease | PrognosisEstimate prognosis in Hodgkin's disease.Hematopoietic cell transplantation - specific comorbidity index (HCT-CI)MDS Revised - International Prognostic Scoring System (IPSS-R)Assess mortality and progression to acute myeloid leukemia in myelodysplastic syndromeHodgkin's Marrow InvolvementEstimate likelihood of bone marrow involvement in Hodgkin's lymphoma.MDS Intnl Prognostic Scoring Sys (IPSS)Multiple Myeloma Prognosis (ISS)MASCC Febrile Neutropenia RiskAssess risk in febrile neutropenia and appropriateness for outpatient managementMDS Anemia - EPO/GCSF ResponseIdentify those with MDS likely to respond to stem-cell factors.MDS WHO Classification-based Prognostic Scoring System (WPSS)Estimate survival and risk of transformation to AML in myelodysplastic syndrome.MGUS PrognosisDetermine risk of malignant progression to myleoma or lymphoproliferative disorder.MIPI - Mantle Cell Lymphoma PrognosisEstimate prognosis in mantle cell lymphoma.DIPSS Prognosis in MyelofibrosisEstimate prognosis in myelofibrosis.Smoldering Multiple Myeloma PrognosisDetermine risk of progression to symptomatic multiple myeloma.Diffuse Large B-cell Lymphoma Prognosis (IPI24)Determine prognosis in diffuse large B-cell lymphoma.Diffuse Large B-cell Lymphoma Prognosis (NCCN-IPI)Estimate prognosis in diffuse large B-cell lymphomaDIPSS Plus Score for Prognosis in MyelofibrosisEstimate prognosis in myelofibrosis.Multiple Myeloma Prognosis (R-ISS)Revised international staging system for myelomaCLL-IPIThe International Prognostic Index for patients with chronic lymphocytic leukemiaMDS Revised - International Prognostic Scoring System (IPSS-R) Non-Age AdjustedAssess mortality and progression to acute myeloid leukemia in myelodysplastic syndrome using the non-age adjusted model
Sponsored
CNS International Prognostic Index in Diffuse Large B-Cell Lymphoma (CNS-IPI)Estimate risk of CNS relapse/progression in diffuse large B-cell lymphomaMALT Lymphoma prognosis (MALT-IPI)Estimate prognosis in MALT lymphomaKhorana risk scoreEstimate risk of chemotherapy-associated thrombosisCLL BALL Score for Relapsed/Refractory CLLSokal Score for CMLEstimate survival in CMLEUTOS Score for Chronic Myelogenous Leukemia (CML)Predict outcomes after CML treatment, adjusted for tyrosine kinase treatments CMML CPSS-MolEstimate risk of progression to AML in those with CMML using molecular genetics dataInternational Prognostic Scoring System for Waldenstrom MacroglobulinemiaEstimate prognosis with the IPPSWM
Renal Cell Carcinoma
Solid Tumor
Carboplatin AUC Dosing (Calvert)Brain Metastases Prognostic IndexEstimate prognosis in patients with brain metastases using the graded prognostic assessmentSerious Illness Conversation GuideSteps to elicit important information from your patients about their goals and valuesKhorana risk scoreEstimate risk of chemotherapy-associated thrombosisTNM Staging for Lung Cancer (AJCC 2017)Classify lung cancer using the TNM staging systemcTNM Staging for Lip and Oral Cavity CancerClassify lip and oral cavity cancer using the clinical TNM staging system (AJCC 2017)pTNM Staging for Lip and Oral Cavity Cancer (AJCC 2017)Classify lip and oral cavity cancer using the pathological TNM staging systemcTNM Staging for Major Salivary Gland Cancer (AJCC 2017)Classify major salivary gland cancer using the clinical TNM staging systempTNM Staging for Major Salivary Gland Cancer (AJCC 2017)Classify major salivary gland cancer using the pathological TNM staging systemTNM Staging for Nasopharyngeal Cancer (AJCC 2017)Classify nasopharyngeal cancer using the TNM staging system
REFERENCE BOOK
Screening for Breast Cancer | CTFPHC
REFERENCE BOOK
Screening for Colorectal Cancer | CTFPHC
REFERENCE BOOK
Screening for Lung Cancer | CTFPHC
REFERENCE BOOK
Screening for Prostate Cancer | CTFPHC
REFERENCE BOOK
Screening for Cervical Cancer | CTFPHC
Orthopedics
Otolaryngology (ENT)
General Otolaryngology
Head & Neck Cancer Staging
Pediatrics
APGARNewborn assessmentSNAP-IV 26 - Teacher & Parent Rating ScaleAssess children for attention deficit hyperactivity disorder (ADHD)Pediatric Endotracheal Tube SizePediatric Glasgow Coma ScalePediatric Strep ScorePELD Score - Age Younger Than 12 yearsPELD (Pediatric End-Stage Liver Disease) is used for liver allocation in the OPTN match systemWestley Croup ScoreAssess croup severityPIM2Paediatric Index of Mortality, revised versionPCDAIPediatric Crohn's Disease Activity IndexPELD Score - Age Younger Than 12 yearsPELD (Pediatric End-Stage Liver Disease) is used for liver allocation in the OPTN match systemCentor Score (modified) for GAS PharyngitisEstimate likelihood of GAS pharyngitisPhiladelphia Criteria in Febrile Infants Identify febrile infants aged 29 – 56 days old who are lower risk for serious bacterial infection Boston Criteria for Febrile InfantsIdentify febrile infants aged 28 – 89 days old who are lower risk for serious bacterial infection Rochester Criteria for Febrile InfantsIdentify febrile infants aged ≤ 60 days old who are low-risk for serious bacterial infectionPECARN Rule for Pediatric Head Injury < 2 years oldAssess the need for neuroimaging in pediatric head trauma PECARN Rule for Pediatric Head Injury ≥ 2 years oldAssess the need for neuroimaging in pediatric head trauma PRAM Score for Pediatric Asthma Exacerbation SeverityAssess asthma severity in pediatric patientsKocher Criteria for Septic ArthritisDetermine risk of septic arthritis in a child with an inflamed hipAlberta Croup Severity
REFERENCE BOOK
Tobacco Smoking in Children and Adolescents | CTFPHC
REFERENCE BOOK
Screening for Developmental Delay | CTFPHCReview Canadian Task Force on Preventive Health Care guideline on screening for developmental delay
REFERENCE BOOK
Obesity in Children | CTFPHC
REFERENCE BOOK
Diagnosis and Management of Congenital Diaphragmatic Hernia (CDH): A Clinical Practice Guideline
Physical Medicine and Rehabilitation
Physiotherapy
Preventive Medicine
ACC/AHA CV Risk Calculator (2013)Estimate 10-year risk for atherosclerotic cardiovascular disease
REFERENCE BOOK
Screening for Breast Cancer | CTFPHC
REFERENCE BOOK
Screening for Cervical Cancer | CTFPHC
REFERENCE BOOK
Screening for Hypertension | CTFPHC
REFERENCE BOOK
Screening for Type 2 Diabetes | CTFPHC
REFERENCE BOOK
Tobacco Smoking in Children and Adolescents | CTFPHC
REFERENCE BOOK
Screening for Colorectal Cancer | CTFPHC
REFERENCE BOOK
Screening for Cognitive Impairment | CTFPHC
REFERENCE BOOK
Screening for Depression | CTFPHC
REFERENCE BOOK
Screening for Developmental Delay | CTFPHCReview Canadian Task Force on Preventive Health Care guideline on screening for developmental delay
REFERENCE BOOK
Screening for Lung Cancer | CTFPHC
REFERENCE BOOK
Obesity in Adults | CTFPHC
REFERENCE BOOK
Obesity in Children | CTFPHC
REFERENCE BOOK
Pelvic Exam | CTFPHC
REFERENCE BOOK
Screening for Prostate Cancer | CTFPHC
REFERENCE BOOK
Screening for Hepatitis C | CTFPHCReview Canadian Task Force on Preventive Health Care guideline on Hepatitis C screening
REFERENCE BOOK
Screening for Abdominal Aortic Aneurysm | CTFPHC
REFERENCE BOOK
Impaired Vision | CTFPHC
REFERENCE BOOK
Screening for Asymptomatic Bacteriuria in Pregnancy | CTFPHC
Respirology
Asthma & COPD
DVT/PE
General Respirology
Lung Cancer
Pneumonia
Sleep
Rheumatology
Ankylosing Spondylitis
Diagnostic criteria
Lupus
Rheumatoid Arthritis
Vasculitis
Surgery
Breast Cancer
Inflammatory Bowel Disease
Preoperative Assessment
Surgical Diagnosis & Management
Trauma
WHO Surgical Safety Checklist
Transplant
Alcohol Relapse Risk after Liver TransplantMELD Score - Age above 12 yearsScoring system used to rank prioritize candidates for liver transplantation, including MELD-Na used in the OPTN match systemPELD Score - Age Younger Than 12 yearsPELD (Pediatric End-Stage Liver Disease) is used for liver allocation in the OPTN match systemPredicting 3 Year Survival for Incident Elderly ESRD PatientsDetermine appropriateness for transplant referral in elderly patients starting dialysisRenal Graft Failure at 5-Years, Predicted 1 Year Post TransplantEstimate the risk of kidney transplant graft failure at 5 yearsRenal Graft Failure at 5-Years, Predicted 7 Days Post TransplantEstimate the risk of kidney transplant graft failure at 5 yearsRenal Graft Failure at 5-Years, Predicted at Time of TransplantEstimate the risk of kidney transplant graft failure at 5 years
Liver
Preoperative Assessment
Renal
Urology
Nephrolithiasis
Preoperative Assessment
Renal Cell Carcinoma
Thrombosis
Urologic disease
WHO Surgical Safety Checklist
Vascular Surgery
Preoperative Assessment
Surgical diagnosis & management
Vascular Quality Initiative Tools
WHO Surgical Safety Checklist
REFERENCE BOOK
Reference book

CSN PD Adequacy Guidelines and Recommendations 2011
References

CSN PD Adequacy Guidelines and Recommendations References
  1. Bargman JM, Bick J, Cartier P, Dasgupta MK, Fine A, Lavoie SD, et al. Guidelines for adequacy and nutrition in peritoneal dialysis. Canadian Society of Nephrology. J Am Soc Nephrol 1999; 10(Suppl 13):S311-21.
  2. Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, et al. on behalf of the Canadian Society of Nephrology. Guidelines for the management of chronic kidney disease. CMAJ 2008; 179 (11):1154-62.
  3. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl 1):S1-266.
  4. Zarnke KB, Campbell NR, McAlister FA, Levine M on behalf of the Canadian Hypertension Recommendations Working Group. A novel process for updating recommendations for managing hypertension: rationale and methods. Can J Cardiol 2000; 16:1094-102.
  5. Culleton BF. Introduction: Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17(Suppl 1):1-3.
  6. Bargman JM, Thorpe KE, Churchill DN on behalf of the CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12:2158-62.
  7. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. on behalf of the Mexican Nephrology Collaborative Study Group. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307-20.
  8. Churchill DN, Taylor DW, Keshaviah PR, and the CANUSA Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996; 7:198-207.
  9. Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang SM, Zhu X, Lazarus JM. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis 1999; 33:523-34.
  10. Rocco M, Soucie JM, Pastan S, McClellan WM. Peritoneal dialysis adequacy and risk of death. Kidney Int 2000; 58:446-57.
  11. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol Dial Transplant 2001; 16:2207-13.
  12. Konings CJ, Kooman JP, Schonck M, Struijk DG, Gladziwa U, Hoorntje SJ, et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study. Nephrol Dial Transplant 2003; 18:797-803.
  13. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003; 64:2238-43.
  14. Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41:1212-18.
  15. Wang AY, Sea MM, Ip R, Law MC, Chow KM, Lui SF et al. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2001; 12:2450-7.
  16. van Olden RW, Krediet RT, Struijk DG, Arisz L. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1996; 7:745-50.
  17. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT on behalf of the NECOSAD Study Group. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002; 62:1046-53.
  18. Ortega O, Gallar P, Carreño A, Gutierrez M, Rodriguez I, Oliet A, et al. Peritoneal sodium mass removal in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis: influence on blood pressure control. Am J Nephrol 2001; 21:189-93.
  19. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003; 139:105-12.
  20. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43:1056-64.
  21. Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 2001; 59:1128-33.
  22. Lui SL, Cheng SW, Ng F, Ng SY, Wan KM, Yip T, et al. Cefazolin plus netilmicin versus cefazolin plus ceftazidime for treating CAPD peritonitis: effect on residual renal function. Kidney Int 2005; 68:2375-80.
  23. Baker RJ, Senior H, Clemenger M, Brown EA. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41:670-5.
  24. Dittrich E, Puttinger H, Schillinger M, Lang I, Stefenelli T, Hörl WH, et al. Effect of radio contrast media on residual renal function in peritoneal dialysis patients-a prospective study. Nephrol Dial Transplant 2006; 21:1334-9.
  25. Kim DJ, Park JA, Huh W, Kim YG, Oh HY. The effect of hemodialysis during break-in period on residual renal function in CAPD patients. Perit Dial Int 2000; 20:784-5.
  26. Jassal SV, Lok CE, Walele A, Bargman JM. Continued transplant immunosuppression may prolong survival after return to peritoneal dialysis: results of a decision analysis. Am J Kidney Dis 2002; 40:178-83.
  27. Bro S, Bjorner JB, Tofte-Jensen P, Klem S, Almtoft B, Danielsen H, et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int 1999; 19:526-33.
  28. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11:556-64.
  29. Rodriguez-Carmona A, Pérez-Fontán M, Garca-Naveiro R, Villaverde P, Peteiro J. Compared time profiles of ultrafiltration, sodium removal, and renal function in incident CAPD and automated peritoneal dialysis patients. Am J Kidney Dis 2004; 44:132-45.
  30. de Fijter CW, Oe LP, Nauta JJ, van der Meulen J, Verbrugh HA, Verhoef J, et al. Clinical efficacy and morbidity associated with continuous cyclic compared with continuous ambulatory peritoneal dialysis. Ann Intern Med 1994; 120:264-71.
  31. Szeto CC, Chow KM, Lam CW, Leung CB, Kwan BC, Chung KY, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrol Dial Transplant 2007; 22:552-9.
  32. Fan SL, Pile T, Punzalan S, Raftery MJ, Yaqoob MM. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73:200-6.
  33. Kim S, Oh J, Kim S, Chung W, Ahn C, Kim SG, et al. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study. Nephrol Dial Transplant 2009; 24:2899-908.
  34. Durand PY, Freida P, Issad B, Chanliau J. How to reach optimal creatinine clearances in automated peritoneal dialysis. Perit Dial Int 1996; 16(Suppl 1):S167-70.
  35. Perez RA, Blake PG, McMurray S, Mupas L, Oreopoulos DG. What is the optimal frequency of cycling in automated peritoneal dialysis? Perit Dial Int 2000; 20:548-56.
  36. Demetriou D, Habicht A, Schillinger M, Hörl WH, Vychytil A. Adequacy of automated peritoneal dialysis with and without manual daytime exchange: a randomized controlled trial. Kidney Int 2006; 70:1649-55.
  37. Blake P, Burkart JM, Churchill DN, Daugirdas J, Depner T, Hamburger RJ, et al. Recommended clinical practices for maximizing peritoneal dialysis clearances. Perit Dial Int 1996; 16:448-56.
  38. Rocco MV, Jordan JR, Burkart JM. Changes in peritoneal transport during the first month of peritoneal dialysis. Perit Dial Int 1995; 15:12-17.
  39. Blake PG, Floyd J, Spanner E, Peters K. How much extra does “adequate” peritoneal dialysis cost? Perit Dial Int 1996; 16(Suppl 1):S171-5.
  40. Blake PG, Korbet SM, Blake R, Bargman JM, Burkart JM, Delano BG, et al. A multicenter study of noncompliance with continuous ambulatory peritoneal dialysis exchanges in US and Canadian patients. Am J Kidney Dis 2000; 35:506-14.
  41. Diaz-Buxo JA. Enhancement of peritoneal dialysis: the PD Plus concept. Am J Kidney Dis 1996; 27:92-8.
  42. Pirpasopoulos M, Rahman M, Lindsay RM, Kennedy AC. A cost-effectiveness study of dwell times in peritoneal dialysis. Lancet 1972; 2:1135-6.
  43. Lo WK, Ho YW, Li CS, Wong KS, Chan TM, Yu AW, et al. Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study. Kidney Int 2003; 64:649-56.
  44. Nevalainen PI, Lahtela JT, Mustonen J, Pasternack A. Subcutaneous and intraperitoneal insulin therapy in diabetic patients on CAPD. Perit Dial Int 1996; 16(Suppl 1):S288-91.
  45. Yang X, Fang W, Bargman JM, Oreopoulos DG. High peritoneal permeability is not associated with higher mortality or technique failure in patients on automated peritoneal dialysis. Perit Dial Int 2008; 28:82-92.
  46. Chung SH, Heimbürger O, Lindholm B. Poor outcomes for fast transporters on PD: the rise and fall of a clinical concern. Semin Dial 2008; 21:7-10.
  47. Tzamaloukas AH. Incremental initiation of peritoneal dialysis: current practice. Adv Perit Dial 1999; 15:175-8.
  48. Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure. J Am Soc Nephrol 2002; 13:2125-32.
  49. Badve SV, Hawley CM, McDonald SP, Mudge DW, Rosman JB, Brown FG, et al. Automated and continuous ambulatory peritoneal dialysis have similar outcomes. Kidney Int 2008; 73:480-8.
  50. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, et al. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000; 11:556-64.
  51. Hufnagel G, Michel C, Queffeulou G, Skhiri H, Damieri H, Mignon F. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 1999; 14:1224-8.
  52. Adachi Y, Nishio A, Ikegami T. Tidal automated peritoneal dialysis preserves residual renal function better than non tidal automated peritoneal dialysis. Adv Perit Dial 2007; 23:98-101.
  53. Konings CJ, Kooman JP, Schonck M, Dammers R, Cheriex E, Palmans Meulemans AP, et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int 2002; 22:477-87.
  54. Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S, et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant 2001; 16:1459-64.
  55. Tzamaloukas AH, Saddler MC, Murata GH, Malhotra D, Sena P, Simon D, et al. Symptomatic fluid retention in patients on continuous peritoneal dialysis. J Am Soc Nephrol 1995; 6:198-206.
  56. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49:1379-85.
  57. Chen W, Cheng LT, Wang T. Salt and fluid intake in the development of hypertension in peritoneal dialysis patients. ren Fail 2007; 29:427-32.
  58. Günal AI, Duman S, Ozkahya M, Töz H, Asçi G, Akçiçek F, et al. Strict volume control normalizes hypertension in peritoneal dialysis patients. Am J Kidney Dis 2001; 37:588-93.
  59. Ate ̧s K, Nergizo ̆glu G, Keven K, Sen A, Kutlay S, Ertürk S, et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 2001; 60:767-76.
  60. Brown EA, Davies SJ, Rutherford P, Meeus F, Borras M, Riegel W, et al. on behalf of the EAPOS Group. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003; 14:2948-57.
  61. Sharma AP, Blake PG. Should “fluid removal” be used as an adequacy target in peritoneal dialysis? Perit Dial Int 2003; 23:107-8.
  62. Kooman JP, Cnossen N, Konings CJ, van der Sande FM, Leunissen KM. Is there a competition between urine volume and peritoneal ultrafiltration in peritoneal dialysis patients? Contrib Nephrol 2006; 150:111-18.
  63. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Pagé D. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-U.S.A. (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1998; 9:1285-92.
  64. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006; 17:2591-8.
  65. Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, et al. Peritoneal equilibration test. Perit Dial Bull 1987; 7:138-47.
  66. Ho-dac-Pannekeet MM, Atasever B, Struijk DG, Krediet RT. Analysis of ultrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis. Perit Dial Int 1997; 17:144-50.
  67. Johnson DW, Mudge DW, Blizzard S, Arndt M, O'Shea A, Watt R, et al. A comparison of peritoneal equilibration tests performed 1 and 4 weeks after PD commencement. Perit Dial Int 2004; 24:460-5.
  68. Campbell NR, Kaczorowski J, Lewanczuk RZ, Feldman R, Poirier L, Kwong MM, et al. on behalf of the Canadian Hypertension Education Program. 2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary-an update of the 2010 theme and the science behind new CHEP recommendations. Can J Cardiol 2010; 26:236-40.
  69. Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, et al. on behalf of the EAPOS Group. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67:1609-15.
  70. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46:496-503.
  71. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16:546-54.
  72. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14:2338-44.
  73. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63:1556-63.
  74. Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003; 64:1480-6.
  75. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001; 21:275-81.
  76. Wolfson M, Piraino B, Hamburger RJ, Morton AR on behalf of the Icodextrin Study Group. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 2002; 40:1055-65.
  77. Rodríguez-Carmona A, Pérez Fontán M, García López E, García Falcón T, Díaz Cambre H. Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study. Perit Dial Int 2007; 27:260-6.
  78. Freida P, Galach M, Divino Filho JC, Werynski A, Lindholm B. Combination of crystalloid (glucose) and colloid (icodextrin) osmotic agents markedly enhances peritoneal fluid and solute transport during the long PD dwell. Perit Dial Int 2007; 27:267-76.
  79. Sav T, Oymak O, Inanc MT, Dogan A, Tokgoz B, Utas C. Effects of twice-daily icodextrin administration on blood pressure and left ventricular mass in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 2009; 29:443-9.
  80. Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL. Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 2003; 18:2364-8.
  81. Azar R, Hogede L, Carru V. Aldactone therapy in a peritoneal dialysis patient. Nephrol Dial Transplant 2003; 18:1232-3.
  82. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant 2006; 21:854-8.
  83. Cocchi R, Degli Esposti E, Fabbri A, Lucatello A, Sturani A, Quarello F, et al. Prevalence of hypertension in patients on peritoneal dialysis: results of an Italian multicentre study. Nephrol Dial Transplant 1999; 14:1536-40.
  84. Koc M, Toprak A, Tezcan H, Bihorac A, Akoglu E, Ozener IC. Uncontrolled hypertension due to volume overload contributes to higher left ventricular mass index in CAPD patients. Nephrol Dial Transplant 2002; 17:1661-6.
  85. Jager KJ, Merkus MP, Boeschoten EW, Dekker FW, Stevens P, Krediet RT. Dialysis in the Netherlands: the clinical condition of new patients put into a European perspective. NECOSAD Study Group. Netherlands Cooperative Study on the Adequacy of Dialysis phase 1. Nephrol Dial Transplant 1999; 14:2438-44.
  86. Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK, Cheung AK. The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2005; 20:1693-701.
  87. Udayaraj UP, Steenkamp R, Caskey FJ, Rogers C, Nitsch D, Ansell D, et al. Blood pressure and mortality risk on peritoneal dialysis. Am J Kidney Dis 2009; 53:70-8.
  88. Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW, et al. on behalf of the Canadian Hypertension Education Program. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II-therapy. Can J Cardiol 2005; 21:657-72.
  89. Wang X, Axelsson J, Lindholm B, Wang T. Volume status and blood pressure in continuous ambulatory peritoneal dialysis patients. Blood Purif 2005; 23:373-8.
  90. Rodríguez-Carmona A, Fontán MP. Sodium removal in patients undergoing CAPD and automated peritoneal dialysis. Perit Dial Int 2002; 22:705-13.
  91. Rabindranath KS, Adams J, Ali TZ, Daly C, Vale L, Macleod AM. Automated vs continuous ambulatory peritoneal dialysis: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2007; 22:2991-8.
  92. Aanen MC, Venturoli D, Davies SJ. A detailed analysis of sodium removal by peritoneal dialysis: comparison with predictions from the three-pore model of membrane function. Nephrol Dial Transplant 2005; 20:1192-200.
  93. Boudville NC, Cordy P, Millman K, Fairbairn L, Sharma A, Lindsay R, et al. Blood pressure, volume, and sodium control in an automated peritoneal dialysis population. Perit Dial Int 2007; 27:537-43.
  94. Davison SN, Jhangri GS, Jindal K, Pannu N. Comparison of volume overload with cycler-assisted versus continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol 2009; 4:1044-50.
  95. Fang W, Oreopoulos DG, Bargman JM. Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 2008; 23:3704-10.
  96. Akbari A, Knoll G, Ferguson D, McCormick B, Davis A, Biyani M. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials. Perit Dial Int 2009; 29:554-61.
  97. McPherson R, Frohlich J, Fodor G, Genest J, on behalf of the Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006; 22:913-27. [Erratum in: Can J Cardiol 2006; 22:1077]
  98. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61:1887-93.
  99. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291:451-9.
  100. Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb- Rumyantzev AS. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2006; 21:2881-92.
  101. Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK. The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis 2007; 50:791-802.
  102. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61:297-304.
  103. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005; 45:119-26.
  104. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and metaregression of randomised controlled trials. BMJ 2008; 336:645-51. [Erratum in: BMJ 2009; 339:b2951]
  105. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. on behalf of the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-48. [Erratum in: N Engl J Med 2005; 353:1640]
  106. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. on behalf of the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395-407. [Erratum in: N Engl J Med 2010; 362:1450]
  107. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010; 160:785-94.e10.
  108. Kronenberg F, Lingenhel A, Neyer U, Lhotta K, König P, Auinger M, et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl 2003; (84):S113-16.
  109. O'Riordan E, O'Donoghue DJ, Kalra PA, Foley RN, Waldek S. Changes in lipid profiles in non diabetic, non nephrotic patients commencing continuous ambulatory peritoneal dialysis. Adv Perit Dial 2000; 16:313-16.
  110. Babazono T, Nakamoto H, Kasai K, Kuriyama S, Sugimoto T, Nakayama M, et al. on behalf of the Japanese Extraneal Collaborated Study Group. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis. Am J Nephrol 2007; 27:409-15.
  111. Brulez HF, van Guldener C, Donker AJ, ter Wee PM. The impact of an amino acid-based peritoneal dialysis fluid on plasma total homocysteine levels, lipid profile and body fat mass. Nephrol Dial Transplant 1999; 14:154-9.
  112. Harris KP, Wheeler DC, Chong CC on behalf of the Atorvastatin in CAPD study investigators. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 2002; 61:1469-74.
  113. Akçiçek F, Ok E, Duman S, Kürsad S, Unsal A, Alev M, et al. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study. Adv Perit Dial 1996; 12:261-5.
  114. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993; 328:1220-5.
  115. Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, et al. on behalf of the Asia Pacific Cohort Studies Collaboration. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004; 110:2678-86.
  116. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc risk 1996; 3:213-19.
  117. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115:450-8.
  118. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104:3046-51.
  119. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21-7.
  120. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. on behalf of the FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-61. [Errata in: Lancet 2006; 368:1415; and Lancet 2006; 368:1420]
  121. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-18.
  122. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. Arch Intern Med 2005; 165:725-30.
  123. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterolincreasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45:185-97.
  124. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC on behalf of the Veterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) investigators. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004; 66:1123-30.
  125. Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 2007; 16:352-8.
  126. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004; 13:417-26.
  127. Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv ren replace Ther 2003; 10:133-45.
  128. Tonelli M, Wiebe N, Culleton B, Lee H, Klarenbach S, Shrive F, et al. on behalf of the Alberta Kidney Disease Network. Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. Nephrol Dial Transplant 2007; 22:2856-66.
  129. Bard JM, Dallongeville J, Hagen E, Pfister P, Ose L, Fruchart JC, et al. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition. Metabolism 1995; 44:1447-54.
  130. Hagen E, Istad H, Ose L, Bodd E, Eriksen HM, Selvig V, et al. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. Eur J Clin Pharmacol 1994; 46:445-9.
  131. Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Arch Intern Med 1993; 153:1321-9.
  132. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. on behalf of the American College of Cardiology and the American Heart Association Task Force on Practice Guidelines, Committee on the Management of Patients with Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article. Circulation 2003; 107:149-58.
  133. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, et al. on behalf of the American College of Cardiology and the American Heart Association Task Force on Practice Guidelines, Committee on the Management of Patients with Chronic Stable Angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article. J Am Coll Cardiol 2003; 41:159-68.
  134. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. on behalf of the American College of Cardiology and the American Heart Association Task Force on Practice Guidelines, Committee on the Management of Patients with Unstable Angina. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article. Circulation 2002; 106:1893-900.
  135. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. on behalf of the American College of Cardiology and the American Heart Association, Committee on the Management of Patients with Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article. J Am Coll Cardiol 2002; 40:1366-74.
  136. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused update of the ACC/ AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008; 117:296-329. [Erratum in: Circulation 2008; 117:e162]
  137. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154-235.
  138. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46:e1-82. [Erratum in: J Am Coll Cardiol 2006; 47:1503-1505]
  139. Hemmelgarn BR, Southern D, Culleton BF, Mitchell LB, Knudtson ML, Ghali WA on behalf of the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) investigators. Survival after coronary revascularization among patients with kidney disease. Circulation 2004; 110:1890-5.
  140. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41:1438-44.
  141. Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, et al. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant 2006; 21:2507-12.
  142. Zannad F, Kessler M, Lehert P, Grünfeld JP, Thuilliez C, Leizorovicz A, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006; 70:1318-24.
  143. Winkelmayer WC, Charytan DM, Levin R, Avorn J. Poor short-term survival and low use of cardiovascular medications in elderly dialysis patients after acute myocardial infarction. Am J Kidney Dis 2006; 47:301-8.
  144. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42:201-8.
  145. Charytan DM, Setoguchi S, Solomon DH, Avorn J, Winkelmayer WC. Clinical presentation of myocardial infarction contributes to lower use of coronary angiography in patients with chronic kidney disease. Kidney Int 2007; 71:938-45.
  146. Charytan D, Mauri L, Agarwal A, Servoss S, Scirica B, Kuntz RE. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J 2006; 152:558-64.
  147. Phakdeekitcharoen B, Leelasa-nguan P. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. Am J Kidney Dis 2004; 44:738-46.
  148. Gross E, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005; 46:94-101.
  149. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004; 15:3192-206.
  150. Stratton RJ, Bircher G, Fouque D, Stenvinkel P, de Mutsert R, Engfer M, et al. Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. Am J Kidney Dis 2005; 46:387-405.
  151. Eustace JA, Coresh J, Kutchey C, Te PL, Gimenez LF, Scheel PJ, et al. Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. Kidney Int 2000; 57:2527-38.
  152. Teixidó-Planas J, Ortiz A, Coronel F, Montenegro J, López-Menchero R, Ortíz R, et al. Oral protein-energy supplements in peritoneal dialysis: a multicenter study. Perit Dial Int 2005; 25:163-72.
  153. González-Espinoza L, Gutiérrez-Chávez J, del Campo FM, Martínez-Ramírez HR, Cortés-Sanabria L, Rojas-Campos E, et al. Randomized, open label, controlled clinical trial of oral administration of an egg albumin-based protein supplement to patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 2005; 25:173-80.
  154. Jones M, Hagen T, Boyle CA, Vonesh E, Hamburger R, Charytan C, et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am J Kidney Dis 1998; 32:761-9.
  155. Li FK, Chan LY, Woo JC, Ho SK, Lo WK, Lai KN, et al. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 2003; 42:173-83.
  156. Tjiong HL, van den Berg JW, Wattimena JL, Rietveld T, van Dijk LJ, van der Wiel AM, et al. Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 2005; 16:1486-93.
  157. Ikizler TA, Wingard RL, Breyer JA, Schulman G, Parker RA, Hakim RM. Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int 1994; 46:1178-83.
  158. Iglesias P, Díez JJ, Fernández-Reyes MJ, Aguilera A, Burgués S, Martínez-Ara J, et al. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am J Kidney Dis 1998; 32:454-63.
  159. Fouque D, Peng SC, Shamir E, Kopple JD. Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. Kidney Int 2000; 57:646-54.
  160. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 1999; 281:1275-81.
  161. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T. Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol 2006; 17:2307-14.
  162. Rammohan M, Kalantar-Zadeh K, Liang A, Ghossein C. Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients. J ren Nutr 2005; 15:345-55.
  163. Wynne K, Giannitsopoulou K, Small CJ, Patterson M, Frost G, Ghatei MA, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebocontrolled trial. J Am Soc Nephrol 2005; 16:2111-18.
  164. Stein A, Moorhouse J, Iles-Smith H, Baker F, Johnstone J, James G, et al. Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 1997; 52:1089-95.
  165. Szeto CC, Wong TY, Chow KM, Leung CB, Li PK. Oral sodium bicarbonate for the treatment of metabolic acidosis in peritoneal dialysis patients: a randomized placebo-control trial. J Am Soc Nephrol 2003; 14:2119-26.
  166. Ross EA, Koo LC. Improved nutrition after the detection and treatment of occult gastroparesis in nondiabetic dialysis patients. Am J Kidney Dis 1998; 31:62-6.
  167. Silang R, Regalado M, Cheng TH, Wesson DE. Prokinetic agents increase plasma albumin in hypoalbuminemic chronic dialysis patients with delayed gastric emptying. Am J Kidney Dis 2001; 37:287-93.
  168. McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 2002; 40:566-75.
  169. Canadian Diabetes Association (CDA). Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Toronto, ON: CDA; 2003.
  170. Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the U.S.: characteristics, glycemic control, and survival. Kidney Int 2006; 70:1503-9.
  171. Khan IH, Catto GR, MacLeod AM. Severe lactic acidosis in patient receiving continuous ambulatory peritoneal dialysis. BMJ 1993; 307:1056-7.
  172. Brier ME, Bays H, Sloan R, Stalker DJ, Welshman I, Aronoff GR. Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. Am J Kidney Dis 1997; 29:907-11.
  173. Abe M, Kikuchi F, Kaizu K, Matsumoto K. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. Clin Nephrol 2007; 68:287-94.
  174. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005; 46:713-19.
  175. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004; 17:365-70.
  176. Selgas R, Diez JJ, Muñoz J, Miranda B, de Alvaro F, Rodriguez JC. Comparative study of two different routes for insulin administration in CAPD diabetic patients. A multicenter study. Adv Perit Dial 1989; 5:181-4.
  177. Huang CC. Treatment targets for diabetic patients on peritoneal dialysis: any evidence? Perit Dial Int 2007; 27(Suppl 2):S176-9.
  178. Bender FH, Bernardini J, Piraino B. Prevention of infectious complications in peritoneal dialysis: best demonstrated practices. Kidney Int Suppl 2006; (103):S44-54.
  179. Torun D, Oguzkurt L, Sezer S, Zumrutdal A, Singan M, Adam FU, et al. Hepatic subcapsular steatosis as a complication associated with intraperitoneal insulin treatment in diabetic peritoneal dialysis patients. Perit Dial Int 2005; 25:596-600.
  180. Tzamaloukas AH, Oreopoulos DG. Subcutaneous versus intraperitoneal insulin in the management of diabetics on CAPD: a review. Adv Perit Dial 1991; 7:81-5.
  181. Riley SG, Chess J, Donovan KL, Williams JD. Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid. BMJ 2003; 327:608-9.
  182. Oyibo SO, Pritchard GM, McLay L, James E, Laing I, Gokal R, et al. Blood glucose overestimation in diabetic patients on continuous ambulatory peritoneal dialysis for end-stage renal disease. Diabet Med 2002; 19:693-6.
  183. Davies SJ, Phillips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
  184. Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GI. What really happens to people on long-term peritoneal dialysis? Kidney Int 1998; 54:2207-17.
  185. Paniagua R, Ventura MD, Avila-Díaz M, Cisneros A, Vicenté-Martínez M, Furlong MD, et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int 2009; 29:422-32.
  186. Holmes C, Mujais S. Glucose sparing in peritoneal dialysis: implications and metrics. Kidney Int Suppl 2006; (103):S104-9.
By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.
Advertisement

Contact us

Do you have an enquiry or suggestion? Get in touch with us through Twitter @QxMD, Facebook QxMD, or email contact@qxmd.com

Transfer results and close
Cancel
Linked calculator